Chemotherapy News and Research

Latest Chemotherapy News and Research

Trovagene receives European patent titled, ‘Methods for Detection of Nucleic Acid Sequences in Urine’

Trovagene, Inc., a developer of trans-renal molecular diagnostics, announced it has received notice of issuance of European Patent No. 2216416 entitled "Methods for Detection of Nucleic Acid Sequences in Urine."

11 May 2012

Fast track approval process for “breakthrough” drugs proposed in the U.S.

Some experimental drugs that show a big effect early in development for treating serious or life-threatening diseases could soon get a faster and cheaper path to U.S. approval, under a proposal likely to become law this year.

10 May 2012

Researchers develop potent new drug that can kill tumor cells

All cells have the ability to recycle unwanted or damaged proteins and reuse the building blocks as food. But cancer cells have ramped up the system, called autophagy, and rely on it to escape damage in the face of chemotherapy and other treatments. Now, researchers at the Perelman School of Medicine; the Abramson Cancer Center; and the School of Arts and Sciences, at the University of Pennsylvania, have developed a potent new drug that clogs up the recycling machinery and kills tumor cells in mouse models.

9 May 2012

IBN develops biochip for investigating the effect of drugs on cancer stem cells

Researchers at the Institute of Bioengineering and Nanotechnology (IBN), the world's first bioengineering and nanotechnology research institute, have developed a miniaturized biochip for investigating the effect of drugs on cancer stem cells (CSCs). Published recently in Nano Today, this new technology could boost the development of more effective cancer drugs.

9 May 2012

Advaxis commences enrollment in ADXS-HPV Phase 1/2 study for head and neck cancer

Advaxis, Inc.,, a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced that two patients have been enrolled into REALISTIC, a Phase 1/2 study being sponsored by Cancer Research UK (CRUK) to investigate the use of ADXS-HPV for the treatment of HPV positive head and neck cancer. HPV is associated with 40-70% of head and neck cancers.

8 May 2012

Can curry really be beneficial for cancer?

Curcumin is found in the spice turmeric has been linked to a range of health benefits. Studies have already shown that it can beat cancer cells grown in a laboratory and benefits have been suggested in stroke and dementia patients as well. Cucurmin, which acts as an antioxidant and has anti-inflammatory properties, has traditionally been used as an alternative remedy for liver disease, digestive disorders, acne and a range of allergies. Some studies have shown it may slow the spread of cancer, boost the effectiveness of chemotherapy and protect healthy cells from the effects of radiotherapy.

8 May 2012

Maxygen first quarter net loss increases to $2.6 million

Maxygen, Inc., a biopharmaceutical company, today announced financial and business results for the quarter ended March 31, 2012.

8 May 2012

Data from Idera IMO-8400 preclinical studies for SLE and psoriasis presented at AAI meeting

Idera Pharmaceuticals, Inc. today announced data from preclinical studies of IMO-8400, demonstrating a novel mechanism of action that may be applicable to the treatment of systemic lupus erythematosus (SLE) and psoriasis. IMO-8400 is an inhibitor of specific Toll-like receptors (TLRs).

7 May 2012

ADVENTRX first quarter net loss increases to $4.2M

ADVENTRX Pharmaceuticals, Inc. today reported financial results for the first quarter ended March 31, 2012.

7 May 2012

Researchers separate low and high-PSA prostate cancer cells

Prostate cancer cells that defy treatment and display heightened tumor-generating capacity can be identified by levels of prostate specific antigen (PSA) expressed in the tumor cells, a research team led by scientists at The University of Texas MD Anderson Cancer Center reports in the May 3 edition of Cell Stem Cell.

7 May 2012

New study on curcumin for advanced bowel cancer

Compounds found in curry are being investigated as a way of improving drug response in patients with advanced bowel cancer in a new study launched on Monday.

7 May 2012

PDE4 enzyme regulates division of tumour cells and blood vessel growth in cancer tissue

Lung cancer is the leading cause of cancer death throughout the world. Standard treatment methods do not usually result in long-term recovery. In addition to the proliferation of the tumour cells, the growth of blood vessels controls tumors development. The blood vessel growth is controlled by several signalling molecules. Scientists from the Max Planck Institute for Heart and Lung Research in Bad Nauheim and Justus Liebig University Giessen have discovered a molecule that plays a key role in this process. They succeeded in reducing tumour growth in their experiments by blocking the phosphodiesterase PDE4.

5 May 2012

New light on many biological differences between individual breast cancers

New findings presented at Europe's leading breast cancer translational research conference this year shed new light on the many biological differences between individual breast cancers.

4 May 2012

Potential breast cancer patients for new immune-targeting therapies

Breast cancer patients whose tumors express high levels of genes related to immune response are more likely to have their tumor completely eradicated by pre-operative chemotherapy compared to patients with low expression of these genes, Belgian researchers report at the 4th IMPAKT Breast Cancer Conference in Brussels, Belgium.

4 May 2012

Generon commences F-627 Phase II trial in breast cancer

Generon Corporation Ltd. today announced the initiation of a Phase II clinical trial for F-627 after US FDA regulatory clearance. The current study is a Phase II, randomized, multicenter, open-label, active-controlled trial of F-627 in women with breast cancer receiving myelotoxic chemotherapy.

4 May 2012

TGen to lead multidisciplinary search for new drugs that could help treat GBM

The Translational Genomics Research Institute (TGen) will lead a multidisciplinary search for new drugs that could help treat the most common and lethal form of brain cancer.

4 May 2012

Potential ways for doctors to improve hormone receptor-positive breast cancer treatment

American and Spanish researchers have found potential ways for doctors to improve the treatment of hormone receptor-positive breast cancer even if they lack access to costly multi-gene tests, as they report at the 4th IMPAKT Breast Cancer Conference.

4 May 2012

Prostate cancer diagnosis on the rise among U.K. men

Latest figures from Cancer Research UK reveal that the number of men diagnosed with prostate cancer in the UK has risen above 40,000.

4 May 2012

SMC rules abiraterone as too expensive for routine prostate cancer treatment

Cancer Research UK is extremely disappointed that the advanced prostate cancer drug, abiraterone, has been ruled too expensive for routine use by the Scottish Medicines Consortium (SMC).

2 May 2012

Topline, interim results from Celldex Phase 2b EMERGE study of CDX-011 for advanced breast cancer

Celldex Therapeutics, Inc. today announced that interim, topline results of the Phase 2b EMERGE study of CDX-011 in patients with advanced breast cancer will be presented in a webcast on May 23, 2012. Linda Vahdat, MD, Professor of Medicine, Chief of Solid Tumor Service and Director of the Breast Cancer Research Program at Weill Cornell Medical College and the lead investigator of the EMERGE study, will join Celldex on the webcast to discuss data from the study.

2 May 2012